Drug Profile
Hepatitis C vaccine - MiGenTra Egypt
Alternative Names: Bivalent VLP vaccine and adjuvant combination (C-Vaxin) - Cyplasin Biomedical; C-Vaxin; Hepatitis C VLP vaccine - Cyplasin BiomedicalLatest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator C-Pharma
- Developer MiGenTra Egypt
- Class Hepatitis C vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Hepatitis C
Most Recent Events
- 30 Aug 2023 Clinical trials in Hepatitis C (Prevention) in USA (Parenteral) (MiGenTra Egypt pipeline, August 2023)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C(Prevention) in USA (Parenteral)
- 29 Mar 2011 Cyplasin Biomedical is now called Compass Biotechnologies